PURPOSE: Blood oxygenation level-dependent (BOLD)-weighted and vessel-encoded arterial spin labeling (VE-ASL) MRI provide complementary information and can be used in sequence to gauge hemodynamic contributions to cerebrovascular reactivity. Here, cerebrovascular reactivity is assessed using dual echo VE-ASL MRI to understand how VE labeling preparations influence BOLD and ASL contrast in flow-limited and healthy perfusion territories. METHODS: Patients (n = 12; age = 55 +/- 14 years; 6F/6M) presenting with ischemic steno-occlusive cerebrovascular disease underwent 3.0T angiographic imaging, T1 -weighted structural, and planning-free dual echo hypercarbic hyperoxic (i.e., carbogen) VE-ASL MRI. Vasculopathy extent, timecourses, and cerebrovascular reactivity (signal change and Z-statistic) for different VE-ASL images were contrasted across flow territories and Bonferroni-corrected P-values reported. RESULTS: BOLD cerebrovascular reactivity (i.e., long-TE VE-ASL) Z-statistics were similarly sensitive to asymmetric disease (P ≤ 0.002) regardless of labeling scenario. Cerebral blood flow reactivity correlated significantly with BOLD reactivity (Z-statistic). However, BOLD signal changes did not differ significantly between labeling scenarios (P > 0.003) or across territories (P > 0.002), indicating BOLD signal changes in response to carbogen offer low sensitivity to lateralizing disease. CONCLUSION: Dual echo VE-ASL can provide simultaneous cerebral blood flow and qualitative BOLD contrast consistent with lateralizing disease severity in patients with asymmetric steno-occlusive disease. The methodological strengths and limitations of composite BOLD and VE-ASL measurements in the clinic are discussed.
PURPOSE: Blood oxygenation level-dependent (BOLD)-weighted and vessel-encoded arterial spin labeling (VE-ASL) MRI provide complementary information and can be used in sequence to gauge hemodynamic contributions to cerebrovascular reactivity. Here, cerebrovascular reactivity is assessed using dual echo VE-ASL MRI to understand how VE labeling preparations influence BOLD and ASL contrast in flow-limited and healthy perfusion territories. METHODS:Patients (n = 12; age = 55 +/- 14 years; 6F/6M) presenting with ischemic steno-occlusive cerebrovascular disease underwent 3.0T angiographic imaging, T1 -weighted structural, and planning-free dual echo hypercarbic hyperoxic (i.e., carbogen) VE-ASL MRI. Vasculopathy extent, timecourses, and cerebrovascular reactivity (signal change and Z-statistic) for different VE-ASL images were contrasted across flow territories and Bonferroni-corrected P-values reported. RESULTS: BOLD cerebrovascular reactivity (i.e., long-TE VE-ASL) Z-statistics were similarly sensitive to asymmetric disease (P ≤ 0.002) regardless of labeling scenario. Cerebral blood flow reactivity correlated significantly with BOLD reactivity (Z-statistic). However, BOLD signal changes did not differ significantly between labeling scenarios (P > 0.003) or across territories (P > 0.002), indicating BOLD signal changes in response to carbogen offer low sensitivity to lateralizing disease. CONCLUSION: Dual echo VE-ASL can provide simultaneous cerebral blood flow and qualitative BOLD contrast consistent with lateralizing disease severity in patients with asymmetric steno-occlusive disease. The methodological strengths and limitations of composite BOLD and VE-ASL measurements in the clinic are discussed.
Authors: Marta Varela; Joseph V Hajnal; Esben T Petersen; Xavier Golay; Nazakat Merchant; David J Larkman Journal: NMR Biomed Date: 2011-01 Impact factor: 4.044
Authors: Mark W Woolrich; Saad Jbabdi; Brian Patenaude; Michael Chappell; Salima Makni; Timothy Behrens; Christian Beckmann; Mark Jenkinson; Stephen M Smith Journal: Neuroimage Date: 2008-11-13 Impact factor: 6.556
Authors: C Heyn; J Poublanc; A Crawley; D Mandell; J S Han; M Tymianski; K terBrugge; J A Fisher; D J Mikulis Journal: AJNR Am J Neuroradiol Date: 2010-01-14 Impact factor: 3.825
Authors: Reinoud P H Bokkers; Matthias J P van Osch; Catharina J M Klijn; L Jaap Kappelle; Jeroen Hendrikse Journal: J Neurol Neurosurg Psychiatry Date: 2011-03-08 Impact factor: 10.154
Authors: Greg Zaharchuk; Huy M Do; Michael P Marks; Jarrett Rosenberg; Michael E Moseley; Gary K Steinberg Journal: Stroke Date: 2011-07-28 Impact factor: 7.914
Authors: Manus J Donahue; Hans Hoogduin; Peter C M van Zijl; Peter Jezzard; Peter R Luijten; Jeroen Hendrikse Journal: NMR Biomed Date: 2010-12-03 Impact factor: 4.044
Authors: Richard G Wise; Kyle T S Pattinson; Daniel P Bulte; Richard Rogers; Irene Tracey; Paul M Matthews; Peter Jezzard Journal: Magn Reson Imaging Date: 2010-08-04 Impact factor: 2.546
Authors: D M Mandell; J S Han; J Poublanc; A P Crawley; J Fierstra; M Tymianski; J A Fisher; D J Mikulis Journal: AJNR Am J Neuroradiol Date: 2011-03-24 Impact factor: 3.825
Authors: Carlos C Faraco; Megan K Strother; Jeroen C W Siero; Daniel F Arteaga; Allison O Scott; Lori C Jordan; Manus J Donahue Journal: J Cereb Blood Flow Metab Date: 2015-07-15 Impact factor: 6.200
Authors: Geoffrey Warnock; Pinar S Özbay; Felix P Kuhn; Daniel Nanz; Alfred Buck; Andreas Boss; Cristina Rossi Journal: J Cereb Blood Flow Metab Date: 2017-04-19 Impact factor: 6.200
Authors: B A Roach; M J Donahue; L T Davis; C C Faraco; D Arteaga; S-C Chen; T R Ladner; A O Scott; M K Strother Journal: AJNR Am J Neuroradiol Date: 2016-04-07 Impact factor: 3.825
Authors: Travis R Ladner; Manus J Donahue; Daniel F Arteaga; Carlos C Faraco; Brent A Roach; L Taylor Davis; Lori C Jordan; Michael T Froehler; Megan K Strother Journal: J Neurosurg Date: 2016-03-11 Impact factor: 5.115
Authors: Jill B De Vis; Esben T Petersen; Alex Bhogal; Nolan S Hartkamp; Catharina J M Klijn; L J Kappelle; J Hendrikse Journal: J Cereb Blood Flow Metab Date: 2015-02-25 Impact factor: 6.200